Which has better valuation and earnings, ABCL or MGTX?

MeiraGTx has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbCellera Biologics $75.13M 51.22 -$146.41M -$0.54 N/A MeiraGTx $81.39M 12.61 -$114.20M $0.71 15.06

Does the media prefer ABCL or MGTX?

In the previous week, MeiraGTx had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for MeiraGTx and 5 mentions for AbCellera Biologics. MeiraGTx's average media sentiment score of 0.38 beat AbCellera Biologics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbCellera Biologics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TNGX or MGTX?

In the previous week, Tango Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Tango Therapeutics and 6 mentions for MeiraGTx. Tango Therapeutics' average media sentiment score of 0.79 beat MeiraGTx's score of 0.38 indicating that Tango Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to LEGN or MGTX?

In the previous week, Legend Biotech had 3 more articles in the media than MeiraGTx. MarketBeat recorded 9 mentions for Legend Biotech and 6 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.38 beat Legend Biotech's score of 0.09 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VKTX or MGTX?

In the previous week, Viking Therapeutics had 5 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Viking Therapeutics and 6 mentions for MeiraGTx. Viking Therapeutics' average media sentiment score of 0.54 beat MeiraGTx's score of 0.38 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, MGTX or TLX?

Telix Pharmaceuticals has higher revenue and earnings than MeiraGTx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MeiraGTx $81.39M 12.61 -$114.20M $0.71 15.06 Telix Pharmaceuticals $803.79M 4.74 -$7.12M N/A N/A

Does the media favor MGTX or TLX?

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Telix Pharmaceuticals and 6 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.38 beat Telix Pharmaceuticals' score of -0.06 indicating that MeiraGTx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 0 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

MeiraGTx (MGTX) Competitors

$10.69 +0.19 (+1.81%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$10.92 +0.23 (+2.17%)

As of 10/9/2026 07:57 PM Eastern

Compare

MGTX vs. ABCL, TNGX, LEGN, VKTX, and TLX

Should you buy MeiraGTx stock or one of its competitors? MeiraGTx's main competitors and comparable companies include AbCellera Biologics (ABCL), Tango Therapeutics (TNGX), Legend Biotech (LEGN), Viking Therapeutics (VKTX), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MeiraGTx compare to AbCellera Biologics?

AbCellera Biologics (NASDAQ:ABCL) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 28.4% of AbCellera Biologics shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MeiraGTx has a net margin of 19.87% compared to AbCellera Biologics' net margin of -248.83%. MeiraGTx's return on equity of 283.85% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-248.83%	-17.49%	-12.36%
MeiraGTx	19.87%	283.85%	29.39%

MeiraGTx has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$75.13M	51.22	-$146.41M	-$0.54	N/A
MeiraGTx	$81.39M	12.61	-$114.20M	$0.71	15.06

In the previous week, MeiraGTx had 1 more articles in the media than AbCellera Biologics. MarketBeat recorded 6 mentions for MeiraGTx and 5 mentions for AbCellera Biologics. MeiraGTx's average media sentiment score of 0.38 beat AbCellera Biologics' score of 0.00 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbCellera Biologics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbCellera Biologics has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

AbCellera Biologics currently has a consensus target price of $13.38, indicating a potential upside of 6.57%. MeiraGTx has a consensus target price of $24.71, indicating a potential upside of 131.19%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

MeiraGTx beats AbCellera Biologics on 12 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

Tango Therapeutics has higher earnings, but lower revenue than MeiraGTx. Tango Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$53.81M	74.61	-$101.59M	-$0.85	N/A
MeiraGTx	$81.39M	12.61	-$114.20M	$0.71	15.06

MeiraGTx has a net margin of 19.87% compared to Tango Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
MeiraGTx	19.87%	283.85%	29.39%

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tango Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market.

In the previous week, Tango Therapeutics had 1 more articles in the media than MeiraGTx. MarketBeat recorded 7 mentions for Tango Therapeutics and 6 mentions for MeiraGTx. Tango Therapeutics' average media sentiment score of 0.79 beat MeiraGTx's score of 0.38 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tango Therapeutics currently has a consensus target price of $43.46, suggesting a potential upside of 82.53%. MeiraGTx has a consensus target price of $24.71, suggesting a potential upside of 131.19%. Given MeiraGTx's stronger consensus rating and higher possible upside, analysts plainly believe MeiraGTx is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

Summary

MeiraGTx beats Tango Therapeutics on 11 of the 17 factors compared between the two stocks.

How does MeiraGTx compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Legend Biotech has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

MeiraGTx has a net margin of 19.87% compared to Legend Biotech's net margin of -7.21%. MeiraGTx's return on equity of 283.85% beat Legend Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
MeiraGTx	19.87%	283.85%	29.39%

Legend Biotech presently has a consensus price target of $55.50, suggesting a potential upside of 198.07%. MeiraGTx has a consensus price target of $24.71, suggesting a potential upside of 131.19%. Given Legend Biotech's higher possible upside, research analysts plainly believe Legend Biotech is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Legend Biotech had 3 more articles in the media than MeiraGTx. MarketBeat recorded 9 mentions for Legend Biotech and 6 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.38 beat Legend Biotech's score of 0.09 indicating that MeiraGTx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MeiraGTx has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.51	-$296.80M	-$0.25	N/A
MeiraGTx	$81.39M	12.61	-$114.20M	$0.71	15.06

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

MeiraGTx beats Legend Biotech on 12 of the 17 factors compared between the two stocks.

How does MeiraGTx compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and MeiraGTx (NASDAQ:MGTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

Viking Therapeutics currently has a consensus target price of $99.44, suggesting a potential upside of 248.81%. MeiraGTx has a consensus target price of $24.71, suggesting a potential upside of 131.19%. Given Viking Therapeutics' higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78

MeiraGTx has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
MeiraGTx	$81.39M	12.61	-$114.20M	$0.71	15.06

MeiraGTx has a net margin of 19.87% compared to Viking Therapeutics' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
MeiraGTx	19.87%	283.85%	29.39%

Viking Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Viking Therapeutics had 5 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Viking Therapeutics and 6 mentions for MeiraGTx. Viking Therapeutics' average media sentiment score of 0.54 beat MeiraGTx's score of 0.38 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MeiraGTx beats Viking Therapeutics on 10 of the 15 factors compared between the two stocks.

How does MeiraGTx compare to Telix Pharmaceuticals?

MeiraGTx (NASDAQ:MGTX) and Telix Pharmaceuticals (NASDAQ:TLX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

MeiraGTx has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market.

Telix Pharmaceuticals has higher revenue and earnings than MeiraGTx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39M	12.61	-$114.20M	$0.71	15.06
Telix Pharmaceuticals	$803.79M	4.74	-$7.12M	N/A	N/A

MeiraGTx has a net margin of 19.87% compared to Telix Pharmaceuticals' net margin of 0.00%. MeiraGTx's return on equity of 283.85% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Telix Pharmaceuticals	N/A	N/A	N/A

MeiraGTx currently has a consensus target price of $24.71, indicating a potential upside of 131.19%. Telix Pharmaceuticals has a consensus target price of $20.50, indicating a potential upside of 82.87%. Given MeiraGTx's higher probable upside, research analysts plainly believe MeiraGTx is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.78
Telix Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Telix Pharmaceuticals had 5 more articles in the media than MeiraGTx. MarketBeat recorded 11 mentions for Telix Pharmaceuticals and 6 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.38 beat Telix Pharmaceuticals' score of -0.06 indicating that MeiraGTx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MeiraGTx	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	0 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.5% of MeiraGTx shares are held by institutional investors. 7.4% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

MeiraGTx beats Telix Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

Get MeiraGTx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MGTX vs. The Competition

Export

Metric	MeiraGTx	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.36%
P/E Ratio	15.06	13.42	274.13	26.16
Price / Sales	12.61	1,240.95	590.44	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	-152.71	17.17	11.21	6.34
Net Income	-$114.20M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-0.93%	-1.33%	-0.92%	-1.41%
1 Month Performance	-16.81%	-8.44%	-4.46%	-3.48%
1 Year Performance	36.35%	14.02%	6.94%	1.16%

MeiraGTx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MGTX MeiraGTx	3.1316 of 5 stars	$10.69 +1.8%	$24.71 +131.2%	+22.0%	$1.01B	$81.39M	15.06	393	Analyst Upgrade Insider Trade
ABCL AbCellera Biologics	1.2562 of 5 stars	$13.57 -1.5%	$13.38 -1.4%	+112.4%	$4.14B	$66.17M	N/A	562
TNGX Tango Therapeutics	2.6958 of 5 stars	$22.50 -2.5%	$43.46 +93.2%	+225.3%	$3.80B	$62.38M	N/A	137
LEGN Legend Biotech	2.896 of 5 stars	$19.16 +2.1%	$55.79 +191.1%	-42.2%	$3.72B	$1.27B	N/A	2,965	Analyst Forecast
VKTX Viking Therapeutics	3.7459 of 5 stars	$29.15 -0.5%	$99.67 +242.0%	-18.5%	$3.69B	N/A	N/A	65	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MGTX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MeiraGTx (MGTX) Competitors

MGTX vs. ABCL, TNGX, LEGN, VKTX, and TLX

How does MeiraGTx compare to AbCellera Biologics?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Summary

How does MeiraGTx compare to Legend Biotech?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Summary

How does MeiraGTx compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MeiraGTx (MGTX) Competitors

MGTX vs. ABCL, TNGX, LEGN, VKTX, and TLX

How does MeiraGTx compare to AbCellera Biologics?

Do insiders and institutionals believe in ABCL or MGTX?

Is ABCL or MGTX more profitable?

Which has better valuation and earnings, ABCL or MGTX?

Does the media prefer ABCL or MGTX?

Which has more volatility and risk, ABCL or MGTX?

Do analysts prefer ABCL or MGTX?

Summary

How does MeiraGTx compare to Tango Therapeutics?

Which has better valuation & earnings, TNGX or MGTX?

Is TNGX or MGTX more profitable?

Do institutionals and insiders hold more shares of TNGX or MGTX?

Which has more risk & volatility, TNGX or MGTX?

Does the media prefer TNGX or MGTX?

Do analysts recommend TNGX or MGTX?

Summary

How does MeiraGTx compare to Legend Biotech?

Which has more volatility and risk, LEGN or MGTX?

Is LEGN or MGTX more profitable?

Do analysts rate LEGN or MGTX?

Does the media refer more to LEGN or MGTX?

Which has higher valuation and earnings, LEGN or MGTX?

Do institutionals & insiders have more ownership in LEGN or MGTX?

Summary

How does MeiraGTx compare to Viking Therapeutics?

Do analysts rate VKTX or MGTX?

Which has preferable earnings & valuation, VKTX or MGTX?

Is VKTX or MGTX more profitable?

Which has more volatility & risk, VKTX or MGTX?

Do insiders & institutionals have more ownership in VKTX or MGTX?

Does the media refer more to VKTX or MGTX?

Summary

How does MeiraGTx compare to Telix Pharmaceuticals?

Which has more risk and volatility, MGTX or TLX?

Which has higher valuation & earnings, MGTX or TLX?

Is MGTX or TLX more profitable?

Do analysts rate MGTX or TLX?

Does the media favor MGTX or TLX?

Do insiders and institutionals have more ownership in MGTX or TLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGTX vs. The Competition

MeiraGTx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools